178 related articles for article (PubMed ID: 15497523)
21. Adverse events in methotrexate-treated rheumatoid arthritis patients.
Sandoval DM; Alarcón GS; Morgan SL
Br J Rheumatol; 1995 Nov; 34 Suppl 2():49-56. PubMed ID: 8535650
[TBL] [Abstract][Full Text] [Related]
22. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature.
Kaneko Y; Suwa A; Ikeda Y; Hirakata M
Mod Rheumatol; 2006; 16(1):36-8. PubMed ID: 16622722
[TBL] [Abstract][Full Text] [Related]
23. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire).
Fatimah N; Salim B; Nasim A; Hussain K; Gul H; Niazi S
Clin Rheumatol; 2016 May; 35(5):1341-5. PubMed ID: 27053094
[TBL] [Abstract][Full Text] [Related]
24. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
McLean-Tooke A; Aldridge C; Waugh S; Spickett GP; Kay L
Rheumatology (Oxford); 2009 Aug; 48(8):867-71. PubMed ID: 19447771
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report.
Salehi M; Miller R; Khaing M
J Med Case Rep; 2017 Jun; 11(1):174. PubMed ID: 28655345
[TBL] [Abstract][Full Text] [Related]
27. Disease-modifying antirheumatic drugs and organising pneumonia.
Faisal M; Roslan A; Nik Abeed NN; Ban Yu-Lin A
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33408105
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary Intravascular Large B-cell Lymphoma in a Patient Administered Methotrexate for Rheumatoid Arthritis.
Iwami E; Ito F; Sasahara K; Kuroda A; Matsuzaki T; Nakajima T; Abe D; Matsumoto K; Sasaki A; Eguchi K; Terashima T
Intern Med; 2020 Feb; 59(3):429-433. PubMed ID: 31619597
[TBL] [Abstract][Full Text] [Related]
29. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Ghogomu ET; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
J Rheumatol; 2014 Jun; 41(6):1049-60. PubMed ID: 24737913
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary function in patients receiving long-term low-dose methotrexate.
Cottin V; Tébib J; Massonnet B; Souquet PJ; Bernard JP
Chest; 1996 Apr; 109(4):933-8. PubMed ID: 8635373
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
[TBL] [Abstract][Full Text] [Related]
32. High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients-A Preliminary Study.
Sandhu A; Dhir V; Bhatnagar A; Dhawan V; Kaur J; Sood A; Naidu S; Ahmad S; Varma N; Sharma A; Sharma S
Ther Drug Monit; 2017 Apr; 39(2):157-163. PubMed ID: 28107255
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate-related primary hepatic lymphoma in a patient with rheumatoid arthritis.
Miyagawa K; Shibata M; Noguchi H; Hayashi T; Oe S; Hiura M; Abe S; Harada M
Intern Med; 2015; 54(4):401-5. PubMed ID: 25748956
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis.
Ohosone Y; Okano Y; Kameda H; Fujii T; Hama N; Hirakata M; Mimori T; Akizuki M; Ikeda Y
J Rheumatol; 1997 Dec; 24(12):2299-303. PubMed ID: 9415631
[TBL] [Abstract][Full Text] [Related]
35. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
36. [Primary central nervous system methotrexate associated lymphoproliferative disorders in a patient with rheumatoid arthritis].
Uchida Y; Hokkoku K; Hatanaka Y; Kikuchi Y; Tashiro H; Sonoo M
Rinsho Shinkeigaku; 2018 Aug; 58(8):485-491. PubMed ID: 30068810
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety of methotrexate in the treatment of rheumatoid arthritis.
Yazici Y
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S65-7. PubMed ID: 21044436
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate.
Lee WS; Lee SI; Lee MS; Kim SI; Lee SS; Yoo WH
Korean J Intern Med; 2016 Jul; 31(4):779-87. PubMed ID: 26961485
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis.
Hoekstra M; van Ede AE; Haagsma CJ; van de Laar MA; Huizinga TW; Kruijsen MW; Laan RF
Ann Rheum Dis; 2003 May; 62(5):423-6. PubMed ID: 12695153
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
Bianchi G; Caporali R; Todoerti M; Mattana P
Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
